(HealthDay News) — For patients with hypertriglyceridemia, LDL cholesterol, and triglyceride reductions depend of the choice and dose of statin, according to research published in The American Journal of Cardiology.
Björn W. Karlson, MD, PhD, from AstraZeneca and the University of Gothenburg in Sweden, and colleagues used data from the individual patient meta-analysis of statin therapy in at-risk groups: effects of rosuvastatin, atorvastatin, and simvastatin meta-analysis to examine LDL cholesterol and triglyceride reductions in patients with baseline triglycerides of at least 177 mg/dL. Using 15 800 patient exposures to rosuvastatin, atorvastatin, and simvastatin, the least squares mean percentage change from baseline in LDL cholesterol and triglycerides were compared.
The researchers found that the mean reductions in LDL cholesterol varied from −26.9% to −55.5%. Significantly greater reductions in LDL cholesterol were seen for 10 mg to 40 mg rosuvastatin vs equal or double doses of atorvastatin and simvastatin (P<.05). The mean reductions in triglycerides varied from −15.1% to −31.3%.
Significantly greater reductions were seen for rosuvastatin 10 mg vs atorvastatin 10 mg (P<.05); similar reductions were seen for 20 mg to 40 mg rosuvastatin vs equal doses of atorvastatin. Significantly greater reductions were seen for rosuvastatin 20 mg to 40 mg vs equal or double doses of simvastatin (P<.05).
“In patients with hypertriglyceridemia, LDL cholesterol reduction was substantial and dependent on the choice and dose of statin,” the researchers wrote.
Several authors disclosed financial ties to AstraZeneca, which funded the study.